After the 95th "young handsome", he took office!Hanging a market value of 70 billion listed companies

Ye Chen, a world network businessman

Edit Li Danchao

A company with a mature system, a market value of 72.2 billion yuan, and an annual income of over 20 billion yuan, how young can the "talk"?

A few days ago, Chinese biopharmaceuticals replaced the new CEO, and after the 95th, Xie Chengrun took office. He is the son of Xie Bing, founder and executive director of Chinese biopharmaceuticals, and the brother of Xie Qirun, the company's current board chairman.

According to the general announcement, after taking over as CEO, Xie Chengrun will focus on the integration, comprehensive innovation, internationalization, and digitalization of the Chinese biopharmaceutical organization, including corporate strategy, personnel appointment and removal, investment integration, etc. Professional management teams to improve organizational efficiency, drive innovation business, connect external cooperation, and promote the process of global innovation.

For a while, the topics and shots in the business circle all targeted the young man who "comes with high light".

The successor of the "Legendary Family"

In August 1995, Xie Chengrun was born in Seattle, USA. His "Xie family" is well -known in China and Thailand.

Xie Chengrun's great -grandfather is Xie Yichu, a well -known patriotic overseas Chinese and an industrialist from Chaoshan. The business community respects Xie Yichu's entrepreneurial experience: he was born in a poor farmer's family in Chenghai County, Guangdong Province. He was 26 years old in Nanyang. He rented a shop in Bangkok, Thailand. Seed shop. And this small shop is the predecessor of Zhengda Group, which has a deep relationship with China.

After more than 80 years of development, Zhengda Group has become one of the world's largest Chinese multinational companies, forming a business pattern with agriculture, animal husbandry, pharmaceutical, and food industry. In 2020, the Xie family won the list of Thai rich list with a total wealth of $ 32.3 billion. Another information shows that Zhengda Group's total investment in China has reached about 120 billion yuan, bringing over 80,000 jobs. It has actively educated, medical public service side in Chaoshan and other places. Money contributes.

Xie Chengrun belongs to the fourth generation of power in the core management of the group. His position he takes over is one of the hot pharmaceutical sectors in the Zhengda Department.

This is not the first time the Xie family has "enabled" young people to enter the management.

In 2015, Xie Chengrun's sister and Xie Qirun, who were only 23 years old at the time, became chairman and executive director of the board of directors of Chinese biopharmaceuticals, ranking among the youngest large enterprises in China.

According to the data, Xie Chengrun, born in 1995, has a bachelor's degree in economics at the Department of Economics at the University of Pennsylvania and the Master of Management of the Department of Economics of the University of Tsinghua University. According to several media reports, in 2013, Xie Chengrun gave up US citizenship, continued to complete his studies as Chinese citizens, and joined the work of Chinese biopharmaceuticals 5 years later.

Prior to this transfer, Xie Chengrun was chairman of the company's company -Zheng Datianqing Pharmaceutical Group Co., Ltd. (referred to as "Zhengda Tianqing"). After the change of his position, Xie Chengrun held about 21.53%of the shares of Chinese biopharmaceuticals through his wholly -owned company.

At 26.86 billion, the giant wheel of heavy warehouse Kexing

Xie Chengrun's Chinese biopharmaceuticals are giant -level companies in the field of Chinese pharmaceuticals.

"Tianxia.com" learned through the Group's official website that the company's current business covers the entire industry chain of pharmaceutical research and development, intelligent production, and pharmaceutical sales. , Types of Nutritional Medication of Early Intestinal Nutrition.

In recent years, China's pharmaceutical industry has developed rapidly, and Chinese biopharmaceuticals have also shown strong business growth in the market.

According to the 2021 annual report, Chinese biopharmaceutical revenue reached 26.86 billion yuan last year, an increase of 13.6%year -on -year; gross profit was 21.53 billion yuan, an increase of 16.6%year -on -year, and the profit attributable to the parent company's holders was 14.61 billion yuan, an increase of 427.2%year -on -year.

Behind profit growth, on the one hand, the Group's main business has performed well, and the sales proportion of new products and high -gross interest rate products during the year.

In the field of pharmaceuticals and sales, the three treatment fields of anti -tumor, cardiovascular and cerebrovascular and respiratory treatment have contributed about 3.1 billion yuan in revenue to Chinese biopharmaceuticals; of which, anti -tumor drugs increased by 21%, sales amount reached 9.22 billion yuan, accounting for the proportion About 34.3%, the compound growth rate of 4 years is about 55%.

According to the data, the company's revenue of the company's listing of about 12.1 billion yuan within five years, accounting for about 45%of the total revenue ratio, hit a record high, with a compound growth rate of about 58.0%in 4 years; The income ratio is about 24%, and the 4 -year compound growth rate is about 34.8%.

Pharmaceutical magazine Pharm EXEC announced the TOP50 list of global pharmaceutical companies, ranked 40th in Zhongsheng Pharmaceuticals

On the other hand, the strong financial performance of the joint venture, the group's profit and loss of the joint venture and the joint venture increased significantly, making Chinese biopharmaceutical make a lot of money.

Kexing Zhongwei is one of the representatives of the "joint venture". In December 2020, Chinese Biopharmaceuticals contributed 515 million US dollars (about RMB 3.5 billion) to Koxingzhong, holding 15.03%of the company's equity.

As the research and development of China's new crown vaccine, the new crown vaccine developed by Kexing Zhongwei has been approved by more than 60 countries, regions and international organizations to be listed urgently or attached to the market, and entered the World Health Organization Emergency List. A set of statistics at the end of March this year showed that the cumulative supply of Kochi New Crown Vaccine has reached 2.8 billion doses. The efforts of Kexing Zhongwei in the new crown pneumonia's epidemic also reflected in the financial statements of Chinese biopharmaceuticals in the situation of associates and rights. In 2021, the joint venture and joint ventures brought about 13.63 billion yuan in profit contributions to Chinese biopharmaceuticals during the year. After deducting the relevant taxes, the substantial profit contribution contributed about 12.38 billion yuan.

From the financial report, whether it is an independent business or an investment sector, Chinese biopharmaceutical has achieved good results in recent years.

In the hidden concerns under the data, can young people take on a heavy task

In 2015, when Xie Qirun took over as chairman of China Biopharmaceutical, the industry had questioned the experience, management, and determination of young people. Today, Xie Chengrun also needs to resist heavy pressure.

On the one hand, Xie Chengrun's "predecessor" is Li Yi, chairman of the former JP Morgan Chase China. Chinese biopharmaceuticals had high hopes for Li Yi. According to the announcement, Chinese biopharmaceuticals must pay 3.5 million US dollars in cash each year, and at the same time pay their $ 3.5 million awards at the same time. Based on the current exchange rate, the annual salary is about RMB 47.257 million.

After Li Yi took over as the CEO of China Biopharmaceuticals, the stock price of Chinese biopharmaceuticals once exceeded 9 Hong Kong dollars/share, with a total market value of more than 160 billion Hong Kong dollars, becoming the highest share price in the past two years.

However, on the other hand, although Li Yi's tenure data seemed to be beautiful during his tenure, it was difficult to hide the problems faced by old -fashioned pharmaceutical companies behind him.

After Ji Cai became the basic model of purchasing public hospitals, the revenue and profits of the main business of Chinese biopharmaceuticals were affected. It also mentioned in the annual report that the Group actively promoted marketing changes in 2021 to cope with the impact of medical reform policies such as collection and national medical insurance negotiations on the industry. The next response strategy is: to further expand the power to increase the capacity, and the disadvantages are used to increase the strength; at the same time, the cooperation of medical and other Internet e -commerce is further promoted to achieve diversification of the sales model.

Judging from the timeline, before serving as the CEO of Chinese Biopharmaceuticals, Xie Chengrun had practiced military military actively in Zhengda Tianqing.

Zheng Da Tianqing was once known as the "King of the First imitation" and was able to "imitate" key new drugs in the international and domestic market quickly. Since Xie Chengrun joined the management, Zhengda Tianqing's play has begun to change: In 2018, Aurotinib was listed in 2018, marking the trend of the company's combination of imitation drugs to imitation and innovation; since then, Xie Chengrun has proposed another proposal again The business transformation plan of "doing innovative medicines" builds and widen the moat in the development of Zhengda Tianqing in the way of "self -research+cooperation".

According to the data, in 2020, the global sales of the original research products of the company reached about 8.124 billion yuan; in October 2021, more than 40 new drugs reported and developed/declared/declared/declared clinical.

Zheng Datianqing's "transition from imitation" business transformation and exploration is the need for Chinese biopharmaceuticals -better operating profits and more anti -risk product structure.

According to the official statement issued by Chinese Biopharmaceuticals, the new division of labor with Xie Qirun and Xie Chengrun as its core will have its own weight: Among them, the chairman of the board of directors Xie Qilun will focus on the group's strategic planning, international business, capital market operations, and listed companies Related affairs; CEO Xie Chengrun will focus on the operation and management, organizational optimization and effectiveness of all subsidiaries under the listed company.

As the older generation of entrepreneurs retired to the second line, Sister Xie's sister became a microcosm of entrepreneur younger and family succession. CEO CEO of Cobos, Chen Shanshan, Chairman of Jinfu Technology, Zhong Hongtian, Chairman of Jiejie Micro Fiber, Jiang Xiaoying, Director of Xiang Piao Piao ... They are all post -90s successors. Some of the characters, some have brought a new world with the company.

Before letting the younger generation go on the stage, we can see that the family business of Chinese biopharmaceuticals embrace innovation. However, whether the successor who gets the new script can take the lead, it will take a little time to confirm it. After all, success has never been done overnight.

- END -